RT Journal Article
SR Electronic
T1 An integrative multi-omics approach in Sjögren’s Syndrome identifies novel genetic drivers with regulatory function and disease-specificity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.14.20192211
DO 10.1101/2020.09.14.20192211
A1 Teruel, María
A1 Barturen, Guillermo
A1 Martínez-Bueno, Manuel
A1 Barroso, Miguel
A1 Castelli, Olivia
A1 Povedano, Elena
A1 Kerick, Martin
A1 Català-Moll, Francesc
A1 Makowska, Zuzanna
A1 Buttgereit, Anne
A1 PRECISESADS Clinical Consortium
A1 PRECISESADS Flow Cytometry Study Group
A1 Pers, Jacques-Olivier
A1 Marañón, Concepción
A1 Ballestar, Esteban
A1 Martin, Javier
A1 Carnero-Montoro, Elena
A1 Alarcón-Riquelme, Marta E.
YR 2020
UL http://medrxiv.org/content/early/2020/10/01/2020.09.14.20192211.abstract
AB Primary Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration and damage of exocrine salivary and lacrimal glands. The etiology of SS is complex with environmental triggers and genetic factors involved. By conducting an integrated multi-omics study we identified vast coordinated hypomethylation and overexpression effects, that also exhibit increased variability, in many already known IFN-regulated genes. We report a novel epigenetic signature characterized by increased DNA methylation levels in a large number of novel genes enriched in pathways such as collagen metabolism and extracellular matrix organization. We identified new genetic variants associated with SS that mediate their risk by altering DNA methylation or gene expression patterns, as well as disease-interacting genetic variants that exhibit regulatory function only in the SS population. Our study sheds new light on the interaction between genetics, DNA methylation, gene expression and SS, and contributes to elucidate the genetic architecture of gene regulation in an autoimmune population.Competing Interest StatementZuzanna Makowska and Anne Buttgereit are employees of BAYER AG Funding StatementFunding for the preparation of this manuscript has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n115565, resources composed of the financial contribution from the European Unions Seventh Framework Program (FP7/2007-2013) and the EFPIA companies in kind contribution. MT is supported by a Spanish grant from Health Department, Junta de Andalucia (PI/0017/2016) and through the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806975. This Joint Undertaking receives support from the European Unions Horizon 2020 research and innovation programme and EFPIA. EC-M was funded by the Postdoctoral Training Subprogramme Juan de la Cierva-Ministry of Economy and Competitiveness (FJCI_2014_20652). Maria Teruel was supported. We thank Ralf Lesche for the production of RNASeq data and Marc Torres Ciuro for design support. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for each Center participating is provided in Supplementary InformationAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe cohort datasets generated and analyzed during the current study will be available upon request through ELIXIR platform.